Skip to content
ClinCalc Pro
Menu
Ultra-Short Acting Opioid Analgesic

Remifentanil

Brand names: Ultiva

Remifentanil is an ultra-short-acting opioid given by continuous infusion during anaesthesia to provide intense, rapidly titratable analgesia.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Remifentanil is a potent mu-opioid receptor agonist that is rapidly broken down by non-specific plasma and tissue esterases, giving an extremely short, context-insensitive duration of action.

Prescribing in practice

  • Profound respiratory depression, apnoea and marked bradycardia or hypotension occur readily, and chest-wall rigidity can impair ventilation — give only by infusion with airway control and full monitoring by an anaesthetist.
  • Because its effect ceases almost immediately when stopped, plan alternative longer-acting analgesia before emergence to avoid abrupt severe pain.
  • Administer through a dedicated, carefully primed line as the rapid offset makes infusion errors and dead-space boluses clinically significant; acute opioid tolerance and hyperalgesia may occur.

Monitoring

Continuously monitor ventilation, oxygenation, heart rate and blood pressure throughout the infusion and during the transition to post-operative analgesia.

Counselling the patient

  • This is a powerful, very short-acting painkiller used during your anaesthetic.
  • Other pain relief will be arranged for when you wake, as this one wears off almost instantly.

Evidence & guidelines

Remifentanil is a well-established intraoperative opioid valued for its precise, rapidly reversible effect.

Reference: Ultiva SPC; Minto et al. (1997) PK model; AAGBI Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.